Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 04, 2023

Clinical Outcomes of Patients With NSCLC With Uncommon EGFR Mutations Treated With Afatinib vs Osimertinib

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
Oncologist 2023 Apr 28;[EPub Ahead of Print], C Wang, K Zhao, S Hu, W Dong, Y Gong, C Xie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading